The 36 references in paper A. Budnevskiy V., E. Ovsyannikov S., A. Chernov V., E. Drobysheva S., А. Будневский В., Е. Овсянников С., А. Чернов В., Е. Дробышева С. (2014) “Диагностическое значение биомаркеров при обострении хронической обструктивной болезни легких // Diagnostic values of biomarkers in acute exacerbation of chronic obstructive pulmonary disease” / spz:neicon:pulmonology:y:2014:i:4:p:100-104

1
Белевский А.С., ред. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2011 г.): Пер. с англ. М.: Российское респираторное общество; 2012. / Belev' skiy A.S.,ed. Global Strategy on Diagnosis, Treatment and Prevention of Chronic Obstructive Pulmonary Disease (revision of 2011). [Global'naya strategiya diagnostiki, lecheniya i profilaktiki khronicheskoy obstruktivnoy bolezni legkikh (peresmotr 2011 g.): Translated from English. Moscow: Rossiyskoe respiratornoe obshchestvo; 2012 (in Russian).
(check this in PDF content)
2
Будневский А.В., Прозорова Г.Г., Бурлачук В.Т. и др. Возможности комбинированной терапии при тяжелой хронической обструктивной болезни легких. Атмосфера. Пульмонология и аллергология. 2010; 4: 34–38. /Budnevskiy A.V., Prozorova G.G., Burlachuk V.T. et al. Opportunities of combined therapy of severe chronic obstructive pulmonary disease. Atmosfera. Pul'monologiya i allergologiya. 2010; 4: 34–38 (in Russian).
(check this in PDF content)
3
Волкорезов И.А., Будневский А.В., Прозорова Г.Г. Системный анализ клинического течения хронической обструктивной болезни легких у больных с остеопорозом. Вестник новых медицинских технологий. 2010; 1: 29–31. /Volkorezov I.A., Budnevskiy A.V., Prozorova G.G. Systemic analysis of clinical course of chronic obstructive pulmonary disease in patients with osteoporosis. Vestnik novykh meditsinskikh tekhnologiy. 2010; 1: 29–31 (in Russian).
(check this in PDF content)
4
Будневский А.В., Трибунцева Л.В., Яковлев В.Н. и др. Оптимизация амбулаторно-поликлинической помощи больным хронической обструктивной болезнью легких. Системный анализ и управление в биомедицинских системах. 2012; 2: 464–468. / Budnevskiy A.V., Tribuntseva L.V., Yakovlev V.N. et al.Improvement of ambulatory care of patients with chronic obstructive pulmonary disease. Sistemnyy analiz i upravlenie v biomeditsinskikh sistemakh. 2012; 2: 464–468 (in Russian).
(check this in PDF content)
5
Пашкова О.В., Разворотнев А.В., Будневский А.В., Лука' шев В.О.Модель клинического течения хронической обструктивной болезни легких. Системный анализ и управление в биомедицинских системах. 2010; 1: 209–213. /Pashkova O.V., Razvorotnev A.V., Budnevskiy A.V., Lukashev V.O.A model of clinical course of chronic obstructive pulmonary disease. Sistemnyy analiz i upravlenie v biomeditsinskikh sistemakh. 2010; 1: 209–213 (in Russian).
(check this in PDF content)
6
Agusti A., Calverley P.M., Celli B. et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir. Res. 2010; 11: 122.
(check this in PDF content)
7
Agusti A., Sobradillo P., Celli B.Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and medicine. Am. J. Respir. Crit. Care Med. 2011; 183: 1129–1137.
(check this in PDF content)
8
Woodruff P.G.Novel outcomes and end points: biomarkers in chronic obstructive pulmonary disease clinical trials. Proc. Am. Thorac. Soc. 2011; 8: 350–355.
(check this in PDF content)
9
Sin D.D., Vestbo J. Biomarkers in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2009; 6: 543–545.
(check this in PDF content)
10
Han M.K., Agusti A., Calverley P.M. et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am. J. Respir. Crit. Care Med. 2010; 182: 598–604.
(check this in PDF content)
11
Stolz D., Christ'Crain M., Morgenthaler N.G. et al. Copeptin, C reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest. 2007; 131: 1058–1067.
(check this in PDF content)
12
Koutsokera A., Kiropoulos T.S., Nikoulis D.J. et al. Clinical, functional and biochemical changes during recovery from COPD exacerbations. Respir. Med. 2009; 103: 919–926.
(check this in PDF content)
13
Krommidas G., Kostikas K., Papatheodorou G. et al. Plasma leptin and adiponectin in COPD exacerbations: associations with inflammatory biomarkers. Respir. Med. 2010; 104: 40–46.
(check this in PDF content)
14
Markoulaki D., Kostikas K., Papatheodorou G. et al.Hemoglobin, erythropoietin and systemic inflammation in exacerbations of chronic obstructive pulmonary disease. Eur. J. Intern. Med. 2011; 22: 103–107.
(check this in PDF content)
15
Tkacova R., Kluchova Z., Joppa P. et al.Systemic inflammation and systemic oxidative stress in patients with acute exacerbations of COPD. Respir. Med. 2007; 101:
(check this in PDF content)
16
0–1676. 16.Pinto'Plata V.M., Livnat G., Girish M. et al.Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest. 2007; 131: 37–43.
(check this in PDF content)
17
Hurst J.R., Donaldson G.C., Perera W.R. et al.Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 174: 867–874.
(check this in PDF content)
18
Bafadhel M., Clark T.W., Reid C. et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest. 2011; 139: 1410–1418.
(check this in PDF content)
19
Bozinovski S., Hutchinson A., Thompson M. et al.Serum amyloid is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008; 177: 269–278.
(check this in PDF content)
20
Gariani K., Delabays A., Perneger T.V. et al. Use of brain natriuretic peptide to detect previously unknown left ventricular dysfunction in patients with acute exacerbation of chronic obstructive pulmonary disease. Swiss. Med. Wkly. 2011; 141: 298.
(check this in PDF content)
21
Daniels J.M., Schoorl M., Snijders D. et al.Procalcitonin vs C reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest. 2010; 138: 1108–1115.
(check this in PDF content)
22
Quint J.K., Donaldson G.C., Goldring J.J. et al.Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. Chest. 2010; 137: 812–822.
(check this in PDF content)
23
Bafadhel M., McKenna S., Terry S. et al.Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med. 2011; 184: 662–671.
(check this in PDF content)
24
Stolz D., Christ'Crain M., Morgenthaler N.G. et al. Plasma proadrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest. 2008; 134: 263–272.
(check this in PDF content)
25
Giron R., Matesanz C., Garcia'Rio F. et al. Nutritional state during COPD exacerbation: clinical and prognostic implications. Ann. Nutr. Metab. 2009; 54: 52–58. Будневский А.В. и др.Диагностическое значение биомаркеров при обострении хронической обструктивной болезни легких
(check this in PDF content)
26
Martins C.S., Rodrigues M.J., Miranda V.P. et al. Prognostic value of cardiac troponin I in patients with COPD acute exacerbation. Neth. J. Med. 2009; 67: 341–349.
(check this in PDF content)
27
Stolz D., Breidthardt T., Christ'Crain M., et al.Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest. 2008; 133: 1088–1094.
(check this in PDF content)
28
Perera W.R., Hurst J.R., Wilkinson T.M. et al.Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur. Respir. J. 2007; 29: 527–534.
(check this in PDF content)
29
Chang C.L., Robinson S.C., Mills G.D. et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax. 2011; 66: 764–768.
(check this in PDF content)
30
Wood'Baker R., Walters J., Walters E.H. Systemic corticosteroids in chronic obstructive pulmonary disease: an overview of Cochrane systematic reviews. Respir. Med. 2007; 101: 371–377.
(check this in PDF content)
31
Stolz D., Christ'Crain M., Bingisser R. et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007; 131: 9–19.
(check this in PDF content)
32
Schuetz P., Christ'Crain M., Thomann R. et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. J.A.M.A. 2009; 302: 1059–1066.
(check this in PDF content)
33
Daniels J.M., Snijders D., de Graaff C.S. et al.Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2010; 181: 150–157.
(check this in PDF content)
34
Kostikas K., Minas M., Papaioannou A.I. et al.Exhaled nitric oxide in asthma in adults: the end is the beginning? Curr. Med. Chem. 2011; 18: 1423–1431.
(check this in PDF content)
35
Siva R., Green R.H., Brightling C.E. et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur. Respir. J. 2007; 29: 906–913.
(check this in PDF content)
36
Bafadhel M., McKenna S., Terry S. et al.Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebocontrolled trial. Am. J. Respir. Crit. Care Med. 2012; 186: 48–55.
(check this in PDF content)